COUR Pharmaceuticals has secured $105 million in a Series A investment round co-led by Lumira Ventures and Alpha Wave Ventures. The funds will be used to support the advancement of COUR’s myasthenia gravis (MG) and type 1 diabetes (T1D) product candidates into Phase IIa clinical trials. The Roche Venture Fund, Pfizer (as part of the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!